ClinicalTrials.Veeva

Menu

ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

Stanford University logo

Stanford University

Status

Enrolling

Conditions

Non-Hodgkin's Lymphoma
Mycosis Fungoides

Study type

Observational

Funder types

Other

Identifiers

NCT02848274
LYMNHL0134 (Other Identifier)
IRB-32652

Details and patient eligibility

About

The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.

Enrollment

2,000 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

  • Diagnosis of advanced stage MF or SS (Stages IIB - IVB) within 6 months of presentation to the participating center
  • Patients that are expected to have care administered at the participating center or jointly with referring physician(s) where follow-up data would be available

Exclusion Criteria

  • Patients diagnosed with early stage MF/SS (Stages IA-IIA) before progressing to advanced stage
  • Patients diagnosed with advanced MF/SS more than 6 months prior to initial presentation to the participating center
  • Exclude one-time consultation type of new patients.

Trial contacts and locations

13

Loading...

Central trial contact

Tatiana Neal

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems